Trial · NCT07887321
Non-inferiority Trial Omitting Drainage After Robot-assisted Radical prostatectomY
NCT07887321, Not applicable, Not yet recruiting, Shanghai East Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Non-inferiority Trial Omitting Drainage After Robot-assisted Radical prostatectomY. Trials, record NCT07887321. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07887321
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Non-inferiority Trial Omitting Drainage After Robot-assisted Radical prostatectomY
- NCT number
- NCT07887321
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 400 participants, estimated
- Lead sponsor
- Shanghai East Hospital
- Conditions
- Prostate Cancer
- Interventions
- No Pelvic Drain Placement, Pelvic Drain Placement
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall incidence of Clavien-Dindo grade I-V complications within 90 days postoperatively | Up to 90 days after surgery. | The primary endpoint is the occurrence of any Clavien-Dindo grade I-V complication from the end of surgery to postoperative day 90. The non-inferiority margin is set at 10 percentage points (risk difference, no-drain group minus drain group). Non-inferiority will be declared if the upper bound of the two-sided 95% confidence interval of the risk difference is below 10%. |
| Secondary | Major complication rate (Clavien-Dindo grade ≥ III) | Up to 90 days after surgery | Incidence of Clavien-Dindo grade ≥ III complications within 90 days postoperatively, including events requiring interventional, endoscopic, reoperative, or ICU treatment, or life-threatening events. |
| Secondary | Urine leakage or anastomosis-related event rate | Perioperative; Postoperative Day 14, Day 30, and Day 90 | Incidence of imaging-confirmed urine leakage, drain fluid creatinine significantly higher than serum creatinine, or prolongation of urethral catheterization, re-catheterization, percutaneous drainage, or other interventions due to suspected or definite anastomotic problems. |
| Secondary | Symptomatic pelvic fluid collection / lymphocele rate | Day 30 and Day 90 after surgery | Incidence of pelvic fluid collection or lymphocele accompanied by pain, fever, infection, lower-limb edema, compressive symptoms, or requiring antibiotics, puncture, catheterization, readmission, or re-intervention. |
| Secondary | Postoperative recovery and healthcare resource utilization | Up to 90 days after surgery | Length of postoperative hospital stay (core quantitative indicator), with 90-day readmission rate and re-intervention rate recorded concurrently to explain differences in resource utilization. |
| Secondary | Urinary continence recovery rate | 1, 3, and 12 months after surgery | Urinary continence recovery rate, defined as the proportion of participants using 0 pads or 1 security pad per day |
| Secondary | Score on the International Consultation on Incontinence Questionnaire - Short Form (ICIQ-UI SF) | 1, 3, and 12 months after surgery | Unit of Measure: Score on a scale ranging from 0 to 21; higher scores indicate more severe urinary incontinence |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07887321
GET https://conductscience.org/api/trials/v1/NCT07887321/registered